Well that is good news. Looks like they weren’t scared to meet with the FDA after all as a self proclaimed PRO had mentioned. They found a means of financing that wouldn’t be with Aspire and its dilution. Remember most recent biotech partnerships don’t wait for signing until a milestone is achieved, they can pay when they occur with Contingent Value Rights (CVRs), and that can be for any achievement including BTD. So I’m thinking anytime folks.